Abstract:Vector capsid dose-dependent inflammation of transduced liver has limited the ability of adeno-associated virus (AAV) factor IX (FIX) gene therapy vectors to reliably convert severe to mild hemophilia B in human clinical trials. These trials also identified the need to understand AAV neutralizing antibodies and empty AAV capsids regarding their impact on clinical success. To address these safety concerns, we have used a scalable manufacturing process to produce GMP-grade AAV8 expressing the FIXR338L gain-of-function variant with minimal (<10%) empty capsid and have performed comprehensive dose-response, biodistribution, and safety evaluations in clinically relevant hemophilia models. The scAAV8.FIXR338L vector produced greater than 6-fold increased FIX specific activity compared with wild-type FIX and demonstrated linear dose responses from doses that produced 2-500% FIX activity, associated with dose-dependent hemostasis in a tail transection bleeding challenge. More importantly, using a bleeding model that closely mimics the clinical morbidity of hemophilic arthropathy, mice that received the scAAV8.FIXR338L vector developed minimal histopathological findings of synovitis after hemarthrosis, when compared with mice that received identical doses of wild-type FIX vector. Hemostatically normal mice (n=20) and hemophilic mice (n=88) developed no FIX antibodies after peripheral intravenous vector delivery. No CD8(+) T cell liver infiltrates were observed, despite the marked tropism of scAAV8.FIXR338L for the liver in a comprehensive biodistribution evaluation (n=60 animals). With respect to the role of empty capsids, we demonstrated that in vivo FIXR338L expression was not influenced by the presence of empty AAV particles, either in the presence or absence of various titers of AAV8-neutralizing antibodies. Necropsy of FIX(-/-) mice 8-10 months after vector delivery revealed no microvascular or macrovascular thrombosis in mice expressing FIXR338L (plasma FIX activity, 100-500%). These preclinical studies demonstrate a safety:efficacy profile supporting an ongoing phase 1/2 human clinical trial of the scAAV8.FIXR338L vector (designated BAX335).

A Study of Gene Transfer and Expression of Human Clotting Factor IX in Hemophilia B Mice Mediated by Mini-Adenoviral Vector.

In Vitro Expression of Human Clotting Factor IX Minigene Mediated by Mini-adenoviral Vector

High Expression of Human Clotting Factor Ix Cdna in Myoblasts C2c12 Cells and C3h Mice

Skeletal Muscle-Specific Expression of Human Blood Coagulation Factor IX Rescues Factor IX Deficiency Mouse by AAV-mediated Gene Transfer.

Efficient Transfer and Expression of Human Clotting Factor IX Cdna in Neonatal Hemophilia B Mice Mediated by VSV-G Pseudotyped Retrovirus

Gene Therapy for Hemophilia B Mediated by Recombinant Adeno-Associated Viral Vector with Hfixr338a,a High Catalytic Activity Mutation of Human Coagulation Factor IX

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

[Human coagulation factor IX gene therapy in murine hemophilia B by hydrodynamic delivery and site-specific genomic integration]

Expression Of Human Factor Ix Gene In Murine Plasma Through Lentiviral Vector-Infected Haematopoietic Stem Cells

Expression of Human Clotting Factor Ix Mediated by Recombinant Lentiviral Vector in Cultured Cells and Hemophilia B Mice

Optimized Human Factor IX Expression Cassettes for Hepatic-Directed Gene Therapy of Hemophilia B

Preparation of A Recombinant Adeno-Associated Viral Vector with A Mutation of Human Factor Ix in Large Scale and Its Expression in Vitro and in Vivo

Muscle Injection of Raav/mfix to Secrete Clotting Factor IX Corrects the Hemorrhagic Tendencies in Hemophilia B Mice

Efficient Delivery of Human Clotting Factor Ix after Injection of Lentiviral Vectors in Utero

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

Construction and High Expression of Retroviral Vector with Human Clotting Factor IX Cdna in Vitro.

Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.

Regulation and expression of human clotting factor IX cDNA in vitro

Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.

Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial

Transgenic Mice Can Express Mutant Human Coagulation Factor IX with Higher Level of Clotting Activity